



CHINESE-AMERICAN LUNG ASSOCIATION



CALA Happy Friday Seminar

April 15th, 2022

Time: EST 10:30 am; PST: 7:30 am; Beijing time: 10:30pm

Zoom: 849 9682 9273 (Password: 654321)

Leveraging Clues from Stem cells to treat pulmonary arterial hypertension



Jun Yang, PhD

Professor

Department of Physiology, Zhejiang University School of Medicine

Bio: Dr. Jun Yang received her Ph.D. degree from Peking Union Medical College. She carried out post-doctoral studies with Professor Nick Morrell on pulmonary vascular disease at University of Cambridge in 2005 after the training on TGF beta signaling in the USA. She was awarded British Associate of Lung Research and Pfizer European pulmonary vascular disease research young investigator first prize. In 2014, she established an independent group to deploy the stem cell based pulmonary arterial hypertension (PAH) model system to study the role of BMPRII signaling pathway in pulmonary vascular disease. Her group applied stem cell technology on drug screening for small molecular intervention of pulmonary arterial hypertension. She has published more than 30 research papers as first or correspondent author in reputable journal, including European Respiratory Journal, Circulation Research, etc. She is also a young leader of National Key Research and Development Program -Stem Cell project.

Abstract: Recently by using CRISPR/Cas9 and Single-cell RNA sequencing techniques, she has shown that; (a). BMPR2 mutation regulates right ventricular function via inhibition of DNA (ID) genes in congenital heart disease (CHD)-PAH. (b). Identified a compound BUR1 with a new chemical structure by targeting deficient BMPR2 signalling to improve pulmonary vascular remodelling. She aims to further understand the role of endothelial stem/progenitor cell in pulmonary hypertension and apply cell therapy in pulmonary vascular disease.